Hepion Pharmaceuticals (NASDAQ:HEPA) said five abstracts have been accepted for poster presentations at the European Association for the Study of the Liver (EASL) International Liver Congress taking place June 22 – 26, 2022 in London and digitally.
The abstracts for poster presentations are:
- Synergistic anti-tumor activity with a combination of anti-PD1 antibody and the cyclophilin inhibitor, rencofilstat, in the Hep53.4 fatty liver model of hepatocellular carcinoma.
- Rencofilstat, a pan-cyclophilin inhibitor, exerts diverse metabolic and transcriptional anti-tumor activities in a murine NASH-HCC model.
- Integrated transcriptomics of rencofilstat treatment in a Phase 2a NASH trial confirms anti-fibrotic effect of pan-cyclophilin inhibition and identifies rencofilstat-specific biomarkers.
- Cyclophilin D knockout promotes cell death pathways in preventing HCC development in a streptozotocin-induced mouse model of diabetes-linked NASH.
- And cyclophilin inhibitor CRV431 as a potential therapy for Alcohol-related Liver Diseases.
